Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06842186
PHASE1

A Phase 1 Study of WVE-007 in Adults Living With Overweight or Obesity

Sponsor: Wave Life Sciences Ltd.

View on ClinicalTrials.gov

Summary

The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of WVE-007 when administered subcutaneously (SC) as single ascending doses in adults who are affected by overweight or obesity.

Official title: A Phase 1, Randomized, Double-blind, Placebo-controlled Study of Ascending Doses of WVE-007 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Adults Living With Overweight or Obesity

Key Details

Gender

All

Age Range

18 Years - 60 Years

Study Type

INTERVENTIONAL

Enrollment

136

Start Date

2025-01-31

Completion Date

2026-10

Last Updated

2026-02-10

Healthy Volunteers

Yes

Interventions

DRUG

WVE-007

Stereopure siRNA oligonucleotide

Locations (6)

Parexel International-EPCU Baltimore

Baltimore, Maryland, United States

ARENSIA Research Clinic

Chisinau, Moldova

Arensia Clinics S.R.L.

Bucharest, Romania

Spitalul Clinic Judetean De Urgenta Cluj

Cluj-Napoca, Romania

Parexel International Early Phase Clinical Unit

Harrow, United Kingdom

Simbec-Orion Clinical Pharmacology

Merthyr Tydfil, United Kingdom